TG Therapeutics

TGTXApproved

TG Therapeutics is a publicly traded biopharmaceutical company dedicated to advancing innovative therapies for patients with B-cell-mediated diseases. Its primary achievement is the FDA approval and commercialization of BRIUMVI® (ublituximab) for relapsing multiple sclerosis, a significant milestone that has transitioned the company to a commercial entity. The company's strategic direction involves maximizing the commercial potential of BRIUMVI, expanding its label, and advancing its pipeline in oncology and autoimmune indications. TG Therapeutics operates with a focused mission to leverage scientific advances to develop superior treatment options.

Market Cap

$4.8B

Focus

AntibodiesBiologics

TGTX · Stock Price

USD 30.09+20.12 (+201.81%)

Historical price data

AI Company Overview

Technology Platform

Glycoengineered monoclonal antibody platform focused on enhancing antibody-dependent cellular cytotoxicity (ADCC) for targeted B-cell depletion, primarily through anti-CD20 therapies.

Pipeline Snapshot

43 drugs in pipeline, 10 in Phase 3

Drug	Indication	Stage
Ublituximab	Multiple Sclerosis	Approved
Ublituximab + Ocrelizumab	Multiple Sclerosis	Approved
Ublituximab + Teriflunomide + Oral Placebo + IV Placebo	Relapsing Multiple Sclerosis (RMS)	Phase 3
Ublituximab + Placebo	Relapsing Multiple Sclerosis	Phase 3
Obinutuzumab + Ublituximab + TGR-1202 + Chlorambucil	Chronic Lymphocytic Leukemia	Phase 3

Funding History

Total raised: $220M

PIPE$125MRA Capital ManagementDec 15, 2020

IPO$60MUndisclosedFeb 5, 2015

Series B$25MUndisclosedJun 15, 2013

Series A$10MUndisclosedJan 15, 2012

FDA Approved Drugs

BRIUMVIBLADec 28, 2022

Opportunities

Significant growth opportunity lies in capturing market share in the large and growing multiple sclerosis therapeutics market with BRIUMVI's differentiated profile (1-hour infusion, glycoengineered potency).

Further opportunities include potential label expansion for BRIUMVI into other autoimmune indications and the development of its early-stage oncology pipeline, which could open new, substantial markets in hematologic cancers.

Risk Factors

Key risks include intense commercial competition in the MS market from well-established rivals, potential pricing and reimbursement challenges, reliance on a single commercial product for revenue, and the inherent risks of clinical failure for early-stage pipeline assets.

Execution of the commercial launch is critical to near-term survival and growth.

Competitive Landscape

BRIUMVI's main competitors in relapsing MS are Roche's Ocrevus (ocrelizumab) and Novartis's Kesimpta (ofatumumab). Differentiation is based on BRIUMVI's glycoengineered design for enhanced B-cell depletion and a shorter one-hour maintenance infusion time. In hematology, the company's pipeline would compete with entrenched BTK inhibitors and a wide array of novel therapies.

Publications

Patents

Pipeline

FDA Approvals